Latest Safety News

PYC Therapeutics has reported positive safety outcomes from its Phase 1 trial of PYC-001 for Autosomal Dominant Optic Atrophy, paving the way for a global Phase 1/2 study later this year.

Guzman y Gomez reports robust Q1 FY26 sales growth and network expansion, alongside a significant $100 million share buyback to enhance shareholder value.

Altech Batteries has achieved a major milestone with its Silumina Anodes™, delivering 88.5% capacity retention after 500 cycles and a 40% capacity boost over graphite anodes. This advancement promises longer electric vehicle ranges and lighter battery packs.

Alliance Aviation Services announces founder Scott McMillan will step down as Joint Managing Director at the November AGM, with Stewart Tully set to become sole Managing Director, concluding a year-long succession plan.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Altech Batteries, in partnership with AMPower, has launched a next-generation 384 V / 15 kWh sodium nickel chloride UPS battery designed specifically for Europe's pipeline infrastructure, promising enhanced safety and reliability in explosive environments.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.

Acusensus Limited has landed its first major automated enforcement contract in the US with Connecticut, marking a significant milestone in its American growth strategy. The five-year deal, valued at US$22.6 million, will see the deployment of AI-enabled speed enforcement technology across work zones.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

Electro Optic Systems has landed a significant A$108 million contract to supply remote weapon systems for the Australian Defence Force’s LAND 400-3 project, integrating its technology with Hanwha’s Redback Infantry Fighting Vehicles.

Locksley Resources has gained critical regulatory approval and secured contractors to advance its Mojave Project, accelerating exploration of antimony and rare earth elements in California.